Data compiled by Redley Lamar · ChainSifter Intelligence
4Suppliers
4Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
Assembly Biosciences, Inc. (ASMB) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
12Total relationships
2Distinct source URLs
6High confidence
0.788Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Assembly Biosciences, Inc. Suppliers
Ticker
Name
Confidence
Evidence
GUGGENHEIM-SECURITIES-LLC
GUGGENHEIM-SECURITIES-LLC
92%
On May 21, 2026, Assembly Biosciences, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Guggenheim Securities, LLC ("Guggenheim Securities") and UBS Sec…
UBS-SECURITIES-LLC
UBS-SECURITIES-LLC
92%
On May 21, 2026, Assembly Biosciences, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Guggenheim Securities, LLC ("Guggenheim Securities") and UBS Sec…
Reciprocal relationship from GILD graph: Reciprocal relationship from ASMB graph: Reciprocal relationship from GILD graph: Reciprocal relationship from ASMB graph: Reciprocal relationship from GILD g…
Reciprocal relationship from MTC graph: Reciprocal relationship from ASMB graph: Reciprocal relationship from MTC graph: . (“OPIM”) is a leading asset management company based in Hong Kong, and a mem…
Reciprocal relationship from GILD graph: Reciprocal relationship from ASMB graph: Reciprocal relationship from GILD graph: Reciprocal relationship from ASMB graph: Reciprocal relationship from GILD g…
nd ABI-1179 (1179); (2) an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, ABI-6250 (6250); and (3) a highly potent next-generation capsid assembly modulator (CAM) designed to disrup…
CAPITAL-RESOURCES
CAPITAL-RESOURCES
62%
ccelerated funding that we received under the First Amendment to the Gilead Collaboration Agreement, which was creditable against future payments. Gilead received an exclusive license to 5366 and 117…
DELAWARE-GENERAL-CORPORATION
DELAWARE-GENERAL-CORPORATION
62%
manufacturers with whom we contract could be foreign, which increases the risk of shipping delays and adds the risk of import restrictions. • We do not have complete control over, and cannot ensure, …
Assembly Biosciences, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
ASMB-DEBT-7882
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2013-12-31.
ASMB-DEBT
Debt stack $419,380
90%
Market cache reports total debt of $419,380.
ASMB-DEBT-7881
Warrants outstanding: 1040820
90%
xbrl warrant detail from xbrl 2025-12-31.
Assembly Biosciences, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Assembly Biosciences, Inc..
Assembly Biosciences, Inc. Ownership
Holder
Name
Confidence
Evidence
ASMB-OWNER-GILEAD-SCIENCES-INC
GILEAD SCIENCES, INC.
90%
13F overlay lists GILEAD SCIENCES, INC. as top holder; 75 tracked holders.
Assembly Biosciences, Inc. Extended Supply Chain Network
